Nervous System Diseases clinical trials at UC Health
5 in progress, 1 open to eligible people
EDS in Ataxia Telangiectasia Patients
open to eligible people ages 6 years and up
This is an international, multi-center, one-year, randomized, prospective, double-blind, placebo-controlled, phase III study, designed to assess the effect of two non-overlapping dose ranges of EDS EP, administered by IV infusion once per month, on neurological symptoms of patients with Ataxia Telangiectasia.
at UCLA
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Sorry, in progress, not accepting new patients
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD
at UCLA
Human Epilepsy Project 2: Resistant Focal Seizures Study
Sorry, in progress, not accepting new patients
The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.
at UCSF
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Sorry, in progress, not accepting new patients
This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
at UC Davis UCSF
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
Sorry, in progress, not accepting new patients
Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.
at UCSF
Last updated: